Streetbeat News

Products Services

VIRX

Viracta Therapeutics announced positive topline results from Stage 1 of the NAVAL-1 trial for Nana-val, a combination treatment for Epstein-Barr Virus-Positive Peripheral T-Cell Lymphoma. The treatment showed a 50% overall response rate and a 20% complete response rate in the intent-to-treat population, with even higher efficacy in the efficacy-evaluable population. The results, which demonstrate greater efficacy than nanatinostat monotherapy, were presented at a joint annual congress in Taiwan.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:02 pm

VCIG

VCI Global Limited (NASDAQ:VCIG) has acquired two AI gamification platforms, ENGAGE and Interact, from a UK-based developer, aiming to tap into the growing mobile advertising market projected to reach $400 billion by 2024. These platforms, which have shown significant user engagement and brand partnerships during trials, are expected to open new monetization channels for VCIG in brand marketing globally. The acquisition aligns with VCIG's strategy to expand its technology venture portfolio and anticipates future Nasdaq listings for these platforms.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:02 pm

KBR

KBR Inc has entered into an exclusive global alliance with GeoLith SAS to license GeoLith's advanced Direct Lithium Extraction technology, Li-Capt, aimed at enhancing lithium production for electric vehicle batteries. This collaboration combines GeoLith's technology with KBR's battery material technologies to produce battery-grade lithium, addressing the growing demand for lithium-ion batteries.

Portfolio Pulse from Shivani Kumaresan

April 15, 2024 | 11:55 am

BMRA

Biomerica, Inc. (NASDAQ:BMRA) announces significant advancements and expansion of its inFoods IBS product, including the activation of over 30 new GI physician groups nationwide and discussions with large non-GI physician groups. This expansion reflects growing adoption within the medical community and positions the company for increased product revenue growth.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 11:54 am

PEV

Phoenix Motor Inc. (NASDAQ:PEV) shares surged in premarket trading after the company provided strong revenue guidance for Q1 FY24, forecasting $8 million-$9 million compared to $1.8 million in Q1 2023. The increase is attributed to strategic initiatives, including acquiring Proterra's transit business and launching new products. CEO Denton Peng highlighted the company's focus on electric vehicles and sustainable transportation. Additionally, Phoenix Motor plans to open an AI development center in Silicon Valley and has partnered with InductEV for wireless charging technology integration.

Portfolio Pulse from Lekha Gupta

April 15, 2024 | 11:49 am

NIO

Nio Inc.'s ADR shares (NYSE:NIO) saw a premarket increase of 1.46% to $4.17, driven by the announcement of unveiling the 2024 ET5 sedan and ES7 SUV at the Beijing International Automotive Exhibition. The company aims to showcase its advancements in AI, smart power, manufacturing, and chip development, along with its customer experience showroom, the Nio House. Nio's move into the low-end market with a new sub-brand positions it as a significant competitor to Tesla in China, the world's largest EV market.

Portfolio Pulse from Shanthi Rexaline

April 15, 2024 | 11:40 am

MRNS

Marinus Pharma announced preliminary Q1 net product revenue of $7.4M-$7.6M from ZTALMY's U.S. launch, with cash holdings of $113.3M as of March 31, 2024.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 11:38 am

CVRX

CVRx announced the availability of additional data highlighting the long-term sustained benefits of Barostim therapy in heart failure patients with reduced ejection fraction. This data supports the effectiveness of Barostim in improving patient outcomes over an extended period.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 11:36 am

IVVD

Invivyd has been granted Healthcare Common Procedure Coding System (HCPCS) reimbursement codes by the U.S. Centers for Medicare & Medicaid Services for its product Pemgarda. This development is crucial for Invivyd as it ensures that Pemgarda will be covered by Medicare and potentially other insurance providers, facilitating access for patients and potentially boosting the product's sales.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 11:34 am

SNGX

The FDA has awarded Soligenix Orphan Drug Designation for the active ingredient in MarVaxor, aimed at the prevention and post-exposure prophylaxis of Marburg virus infection. This designation can provide benefits such as market exclusivity upon approval, assistance in the drug development process, and tax credits.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 11:31 am